Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, Eun Sun | - |
dc.contributor.author | Kim, Kyung-Ah | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Kim, In Hee | - |
dc.contributor.author | Lee, Byung Seok | - |
dc.contributor.author | Lee, Youn Jae | - |
dc.contributor.author | Chung, Woo Jin | - |
dc.contributor.author | Jeong, Sook-Hyang | - |
dc.date.accessioned | 2021-08-11T09:23:34Z | - |
dc.date.available | 2021-08-11T09:23:34Z | - |
dc.date.issued | 2019-12 | - |
dc.identifier.issn | 0146-6615 | - |
dc.identifier.issn | 1096-9071 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4072 | - |
dc.description.abstract | This study aimed to investigate the real-life effectiveness and safety of daclatasvir (DCV) and asunaprevir (ASV) combination therapy in Korean patients. We consecutively enrolled patients with genotype 1b hepatitis C virus (HCV) infection treated with at least one dose of DCV/ASV combination therapy in seven tertiary hospitals of South Korea. The sustained virologic response (SVR) rates and safety according to intention-to-treat (ITT) and per-protocol (PP) analyses were evaluated. Among the 526 enrolled patients, 91% showed negative (87%) or "undetermined" (4%) resistance-associated substitution (RAS); 9% did not undergo RAS testing. The SVR rates for ITT and PP were 89.3% and 95.0% in treatment-naive patients and 93.2% and 95.6% in treatment-experienced patients, respectively. In PP analysis, negative RAS was associated with higher SVR (96.3%) than with "undetermined RAS" (85.7%) or "not tested for RAS" (84.4%). Adverse events were reported in 185 (35.4%) patients, and events leading to discontinuation were observed in 4.3% of the study population. Forty-two (8.0%) patients developed transaminase elevation (>= 2 x upper normal limit), resulting in treatment discontinuation in six (1.1%) patients. DCV/ASV combination therapy showed acceptable efficacy in genotype 1b compensated HCV-infected patients with negative pretreatment RAS. Although most adverse events were tolerable to continue antiviral treatment, adequate monitoring for transaminase elevation is warranted. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | John Wiley & Sons Inc. | - |
dc.title | Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1002/jmv.25575 | - |
dc.identifier.scopusid | 2-s2.0-85072052548 | - |
dc.identifier.wosid | 000485343300001 | - |
dc.identifier.bibliographicCitation | Journal of Medical Virology, v.91, no.12, pp 2158 - 2165 | - |
dc.citation.title | Journal of Medical Virology | - |
dc.citation.volume | 91 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 2158 | - |
dc.citation.endPage | 2165 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | DACLATASVIR PLUS ASUNAPREVIR | - |
dc.subject.keywordPlus | VIRUS-INFECTION | - |
dc.subject.keywordPlus | VARIANTS | - |
dc.subject.keywordPlus | KOREA | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordAuthor | anti-hepatitis C virus DAA | - |
dc.subject.keywordAuthor | antisense drug resistance | - |
dc.subject.keywordAuthor | antiviral agents | - |
dc.subject.keywordAuthor | hepatitis C virus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.